Loading...
Market
Rytelo sales exceed $50 million in Q3 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Geron's quarterly financial report
Story
FDA Approves Geron's Rytelo for Lower-Risk MDS; Shares Surge 30%, Including 22.4% Pre-Market
Jun 7, 2024, 12:10 PM
The U.S. Food and Drug Administration (FDA) has approved Geron's drug Rytelo (imetelstat) for the treatment of patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. This marks the first FDA approval for Geron, a biotech company founded in 1990 by Mike West and Alex Barkas. Following the approval, Geron's shares surged, rising by as much as 30% on Friday, including a 22.4% pre-market increase. The drug, an oligonucleotide telomerase inhibitor, represents a significant advancement in the treatment of blood disorders. The approval has been widely praised by the medical community, with notable endorsements from experts involved in the trial's steering committee, including Mikkael Sekeres from SylvesterCancer.
View original story
Similar markets
Above $1 billion • 33%
Between $500 million and $1 billion • 33%
Below $500 million • 33%
FDA approval for another drug • 33%
Major partnership announcement • 33%
No major milestone • 33%
High (>20% market share) • 33%
Moderate (10-20% market share) • 33%
Low (<10% market share) • 33%
